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INTRODUCTION
The hyper-IgE syndrome (HIES) is a rare disorder of unknown
aetiology, characterized by markedly increased levels of poly-
clonal IgE in serum, elevated levels of blood eosinophils and
recurrent staphylococcal abscesses of the skin, lungs and other
sites [1]. This disorder is also associated with certain facial and
skeletal features such as recurrent fractures, hyperextensible
joints and scoliosis [2]. The genetic basis of HIES is still unclear
since the majority of cases are sporadic. Attempts to link HIES
to variants of the interleukin-4 (IL-4) receptor on chromosome
16 have failed [3], but recently a linkage was found for HIES to
a region on chromosome 4 [4]. No candidate gene on chromo-
some 4 has been implicated but numerous genes have been
mapped near the region, including c-kit and VEGFR-2 [4].
The immunological features of HIES, such as elevated IgE
levels, has prompted studies of IgE synthesis in this syndrome.
These include studies of the elements controlling IgE production
such as the cytokines IL-4, which induces IgE switching, and inter-
feron-g (INF-g), which inhibits IgE switching. Studies of cytokine
production in patients with HIES have given conflicting results.
Decreased IFN-g production compared to healthy controls and
normal or increased IL-4 production have been reported [5–7].
Other studies have shown no difference in IFN-g production in
comparison with controls [8]. The IL-4-like cytokine IL-13 can
induce IgE switching [9,10]. Whether it accounts for the elevated
IgE levels in HIES rather than IL-4 is not known. A recent study
using ELISA, indicated that IL-13 levels were not elevated in
HIES patients when compared to healthy controls, but rather that
IL-4 levels were significantly increased [7]. IL-4 and IL-13 are
produced primarily by activated T cells and mast cells [11] and
the genes for both of these cytokines are located in the same
region on chromosome 5 [11]. The amino acid similarity between
the cytokines is approximately 30% [11]. Additionally, the recep-
tors for the cytokines are structurally similar as one type of the
IL-13 receptor shares the IL-4 receptor a chain [12]. Past studies
have indicated that IL-13 could not regulate T-cell differentiation
because of lack of functional IL-13 receptors on T-cells [9].
However, it has now been shown that T-cells do indeed express a
functional IL-13 receptor which is capable of transducing signals
through signal transducer and activator of transcription 6 (Stat6)
[13,14].
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SUMMARY
Hyper IgE syndrome (HIES) is a rare immunodeficiency disorder characterized mainly by high levels
of polyclonal IgE in serum and recurrent staphylococcal abscesses of the skin and lungs. The raised IgE
levels have led researchers to study the synthesis of cytokines that regulate switching of immunoglob-
ulin production towards IgE such as interleukin-4 (IL-4), IL-12 and interferon-g (IFN)-g. However, the
role of IL-13 in the disease pathogenesis has not been investigated extensively. In this study, we inves-
tigated intracellular expression of IL-4 and IL-13 in mononuclear cells and CD4+ cells isolated from
patients with HIES and healthy controls. Cells were stained intracellularly with antibodies directed
against IL-4 and IL-13 and analysed by flow cytometry before and after activation with PMA and
calcium ionophore. The mean proportion of resting or activated IL-4 and IL-13 expressing mononu-
clear cells were comparable in the two groups as well as the proportion of IL-4 expressing CD4+ cells.
In contrast, the mean proportion of IL-13 expressing CD4+ cells was increased significantly in patients
with HIES in both the resting and the activated state compared to healthy controls. We conclude that
increased expression of IL-13 in CD4+ cells from patients with HIES could account, at least partly, for
raised IgE levels in those individuals.
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The objective of this study was to investigate the expression
of IL-4 and IL-13 in mononuclear cells and CD4+ cells in healthy
blood donors and in patients with the HIES using intracellular
cytokine staining and flow cytometry.
MATERIALS AND METHODS
Reagents
Phorbol 12-myristate 13-acetate (PMA) and calcium ionophore
were purchased from Sigma (St Louis, MO, USA). Monoclonal
antibodies used were anti-CD4 PerCP (Becton Dickinson, 
San Jose, CA, USA), anti-IL-4 PE and anti-IL-13 PE, all from
Pharmingen (San Diego, CA, USA). Isotype controls used 
were mouse IgG1, mouse IgG1 PE, rat IgG1 and rat IgG1 PE
(Pharmingen).
Cells
Peripheral blood was obtained from six healthy blood donors,
three males and three females, with no history of atopic disease,
and from six patients diagnosed with HIES. The patients, three
males and three females, had all been diagnosed with HIES at the
Institute of Child Health, London, University Hospital Nijmegen,
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Fig. 1. Representative flow cytometric analysis of IL-4 expressing CD4+ cells in a normal control and a patient with HIES. (a) FSC versus
SSC profile of mononuclear cells (cells in gate R1). (b) CD4 positive cells from gate R1. (c) IL-4 expressing cells from gate R2 (normal
control) and R3 (HIES), respectively. The percentage of cells shown in (c) was aquired by subtracting the percentage of cells staining 
positive for isotype controls in R2 and R3 from the percentage of IL-4-expressing cells.
534 K. O. Gudmundsson et al.
© 2002 Blackwell Science Ltd, Clinical and Experimental Immunology, 128:532–537
and The Children’s Hospital, Iceland, based on clinical symptoms
including history of recurrent staphylococcal infections, facial and
skeletal features associated with the syndrome and highly ele-
vated serum IgE levels (≥20 000 IU/ml). The age of the patients
at study ranged from 10 to 35 years and the healthy blood donors
from 25 to 35. Mononuclear cells (MNC) were isolated by cen-
trifugation over Histopaque-1077 gradients (Sigma, St Louis, MO,
USA).
Cell culture
MNC (1 ¥ 106/ml) were cultured in 24-well plates (Falcon, NJ,
USA) for 6 h at 37°C and 5% CO2 in AIM-V serum free medium
(Life Technologies, Paisley, UK) supplemented with penicillin,
streptomycin, PMA (100 ng/ml) and calcium ionophore (1 mg/ml).
The protein transport inhibitor brefeldin A (Pharmingen) was
included in all cultures as recommended by the manufacturer. The
optimal concentration of PMA and calcium ionophore and the
kinetics of IL-4 and IL-13 expression was determined by staining
of MNC from a healthy individual. The optimal concentration of
PMA and calcium ionophore was 100 ng and 1 mg, respectively
(data not shown) and the expression of both cytokines peaked at
approximately 6 h (data not shown).
Intracellular cytokine staining
Intracellular cytokine staining was performed using the
Cytofix/CytoPerm Plus Kit (Pharmingen) according to the manu-
facturer’s instructions. Cultured mononuclear cells were washed
twice in AIM-V medium, Fc receptors blocked with unconjugated
irrelevant mouse and rat IgG1 antibodies and then stained with
PerCP conjugated anti-CD4. The cells were then fixed and per-
meabilized with Cytofix/Cytoperm solution and incubated with
PE conjugated monoclonal anti-IL-4 and IL-13. The specificity of
the antibodies was analysed in blocking experiments using uncon-
jugated forms of the same monoclonal antibodies to IL-4 and 
IL-13 (data not shown).
Flow cytometry
The intracellular expression of IL-4 and IL-13 in mononuclear
cells and CD4+ cells was monitored on Becton Dickinson 
FACSCalibur flow cytometer equipped with an argon ion laser. 
A minimum of 20 000 lymphocyte-gated events were aquired 
in list mode and analysed with CellQuest software (Becton 
Dickinson).
Statistical analysis
The Mann–Whitney U-test was used to compare the proportion
of IL-4 and IL-13 expressing cells from healthy control subjects
and HIES patients. The calculations were made using GraphPad
Prism version 3·00 for Windows, GraphPad Software, San Diego,
California USA, www.graphpad.com. The difference was consid-
ered significant if P < 0·05. The results are presented as mean ±
standard error of the mean.
RESULTS
IL-4 expression by MNC and CD4+ cells
No significant difference was found in the proportion of IL-4
expressing MNC from healthy controls and patients with the
HIES, respectively. This was true both for the resting and the acti-
vated state. The mean proportion of resting IL-4 expressing MNC
was 2·00% ± 0·13% in healthy controls but 0·83 ± 0·56 in patients
with the HIES. In activated MNC the mean proportion was 1·62
± 0·13 in healthy controls and 0·62 ± 0·44 in HIES. Similar to
MNC, no significant difference was found in the proportion of IL-
4 expressing CD4+ cells from healthy controls and patients with
the HIES, regardless of whether cells were resting or activated
(Fig. 1). The mean proportion of resting IL-4 expressing CD4+
cells was 4·04 ± 0·41 in healthy controls and 4·21 ± 1·69 in patients
with the HIES. In activated CD4+ cells the mean proportion was
4·37 ± 0·36 in healthy controls and 5·47 ± 2·91 in patients with the
HIES.
IL-13 expression by MNC and CD4+ cells
No significant difference was found in the proportion of IL-13
expressing MNC cells from healthy controls and patients with 
the HIES, regardless of whether cells were resting or activated
(Fig. 2). The mean proportion of resting IL-13 expressing MNC 
was 0·12 ± 0·06 in healthy controls but 0·27 ± 0·10 in HIES. In 
activated MNC the mean proportion was 0·18 ± 0·04 in healthy
controls and 0·30 ± 0·18 in patients with the HIES. In contrast,
significantly increased expression of IL-13 was found between
both resting (P < 0·0411) and activated (P < 0·0420) CD4+
cells from healthy controls and patients with the HIES (Figs 3 and
4). The mean proportion of resting IL-13 expressing CD4+ cells
was 0·26 ± 0·13 in healthy controls and 2·26 ± 1·15 in patients 
with the HIES. In activated CD4+ cells the mean proportion was 
0·32 ± 0·08 in healthy controls and 2·34 ± 1·12 in patients with the
HIES.
DISCUSSION
This study is the first to show that resting or activated CD4+ cells
from patients with the HIES express higher levels of IL-13 com-
pared to healthy controls. In contrast, the levels of IL-4 expres-
sion were similar in the two groups, results that are in agreement
with previous studies [8, 15]. IL-4 expression was similar in both
the mononuclear cell population as well as the CD4+ population
with no differences between resting or activated cells. The reasons
for the differences observed in IL-13 between HIES and controls
0·0
0·1
0·2
0·3
0·4
0·5
%
IL
-1
3 
ex
pr
es
sin
g 
M
NC
N
 IL
-1
3(0
)
H
 IL
-1
3(0
)
N
 IL
-1
3(A
)
H
 IL
-1
3(A
)
Fig. 2. The proportion of IL-13 expressing MNC from normal controls 
(n = 6) and patients with HIES (n = 6) before (0) and after activation (A)
with PMA and calcium ionophore. The results are presented as mean ±
s.e.m. N = normal controls. H = HIES patients.
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are unclear, but may be related to the potential bias in the balance
between Th1 and Th2 in HIES. Recent evidence suggests that
enhancement of IFN-g production by IL-12 in patients with HIES
is significantly lower compared to healthy controls [16]. This could
theoretically favour naive T-cells differentiating into Th2 cells 
and thus have a direct effect on production of cytokines such as
IL-13.
In contrast to the results obtained in our study a previous
study has shown significantly higher IL-4 but similar IL-13 levels
in patients with suspected HIES compared to controls [7]. In this
study, ELISA was used to measure the concentration of IL-4 and
IL-13 in the sera of patients. The differences between the results
of our studies may, however, be methodological, as we studied
intracellular expression of cytokines.
The advantage of the flow cytometer, as used in our study, is
the possibility of studying cytokine-producing cells at the single
cell level. It also has clear advantages over other methods used
for studying cytokine production. The ELISA or ELISPOT 
can be difficult to interpret, mainly because of background stain-
ing and the inherent variability in counting between observers.
This is particularly true where the number of cytokine-producing
cells is low, as is often the case. Flow cytometric analysis also
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Fig. 3. Representative flow cytometric analysis of IL-13 expressing CD4+ cells in a normal control and a patient with HIES. (a) FSC versus
SSC profile of mononuclear cells (cells in gate R1). (b) CD4 positive cells from gate R1. (c) IL-13 expressing cells from gate R2 (normal
control) and R3 (HIES), respectively. The percentage of cells shown in (c) was aquired by subtracting the percentage of cells staining 
positive for isotype controls in R2 and R3 from the percentage of IL-13 expressing cells.
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allows multiple parameters to be studied simultaneously, thus
enabling phenotypic determination of the cytokine producing
cells [17].
Determining the optimal amount of PMA and calcium
ionophore for cell activation as well as the time of cell harvest is
important to detect the point of maximal IL-4 and IL-13 expres-
sion. It has been shown that cell activating agents can differ in
their ability to induce cytokine production, i.e. PMA and calcium
ionophore induce production of Th2 cytokines such as IL-4, IL-5
and IL-10 [18]. The induction of IL-4 and IL-13 expression and
production with polyclonal activation in the human system is
minimal. With our culture conditions, maximal positivity was
detected after approximately 4–8 h (6 h) for both IL-4 and IL-13
(data not shown).
While CD4+ cells are the main source of IL-4 and IL-13 we
also wanted to study the MNC population, because cells other
than those that are CD4+ are capable of producing IL-4 and IL-
13. It has been shown recently that natural killer cells, which often
fall within the MNC gate, are capable of producing IL-13 [19]. In
some instances we had difficulty in gating on CD4+ cells after acti-
vation with PMA and calcium ionophore because of activation-
dependent down-regulation of CD4+ expression, as has been
reported by others [18,20]. While the decrease in CD4 expression
in our studies was substantial the CD4+ population remained
quite distinct from the CD4- population. The mean fluorescence
intensity was decreased in the activated state compared to the
resting state, indicating that the density of CD4 molecules on the
cell surface was reduced.
Because HIES is characterized by skeletal abnormalities it is
interesting to speculate about the role of IL-13 in bone metabo-
lism. Recent experiments have shown that IL-13 has a negative
effect on the growth of osteoblasts as well as stimulating them 
to produce IL-6, a potent osteoclast recruitment factor [21].
Increased levels of IL-13 in HIES could therefore be a factor in
the skeletal features of the syndrome.
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Fig. 4. The proportion of IL-13 expressing CD4+ cells from normal con-
trols (n = 6) and patients with HIES (n = 6) before (0) and after activa-
tion (A) with PMA and calcium ionophore. The difference between the
proportions of IL-13 expressing CD4+ cells in normal controls and patients
with HIES was significant both in the resting and activated state 
(*P < 0·05). The results are presented as mean ± s.e.m. N = normal 
controls. H = HIES patients.
In conclusion, our results indicate that the proportion of 
IL-13 expressing CD4+ cells is higher in patients with HIES com-
pared to healthy controls. A higher proportion of IL-13 express-
ing CD4+ cells could account in part for raised IgE levels in HIES
in combination with decreased IFN-g production.
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